852A

Drug Profile

852A

Alternative Names: 3M-852A; 852; PF-04878691; PF-4878691; S-32865

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Drug Delivery Systems
  • Developer 3M Drug Delivery Systems; Masonic Cancer Center; Pfizer
  • Class Amines; Antineoplastics; Antivirals; Imidazoles; Quinolines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Skin disorders
  • Discontinued Barrett's oesophagus; Haematological malignancies; Hepatitis C; Malignant melanoma; Solid tumours

Most Recent Events

  • 29 Apr 2016 Chemical structure information added
  • 26 Apr 2016 852 is available for licensing as of 26 Apr 2016. http://www.3m.com/3M/en_US/drug-delivery-systems-us/
  • 26 Apr 2016 Phase-I clinical trials in Skin disorders in USA (Topical) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top